SN-38

• Description :

  SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) [1][2][3][4][5].

• CAS Number :

  [86639-52-3]

• Product Name Alternative :

  7-Ethyl-10-hydroxycamptothecin

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  ADC Payload; Autophagy; Drug Metabolite; Topoisomerase

• Type :

  Natural Products

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SN-38.html

• Purity :

  99.94

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O

• Molecular Formula :

  C22H20N2O5

• Molecular Weight :

  392.40

• Precautions :

  H301

• References & Citations :

  [1]Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19 (6) :1493-8.|[2]Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56.|[3]Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51 (16) :4187-4191.|[4]Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  Phase 2

• Isoform :

  Camptothecins; Topo I